California-based Amgen has filed a patent infringement suit to stop Samsung Bioepis from developing bone-treatment drugs that would rival two of its top-performing products.
August 22, 2024 at 07:15 PM
4 minute read
The original version of this story was published on The Recorder
A team from Saul Ewing has appeared on behalf of Samsung Bioepis, which faces a patent infringement complaint from Amgen over development of biologic drugs similar to two of the biopharmaceutical giant’s top-performing products.
William Baton, Sarah Sullivan and Alexander Callo appeared Tuesday in the U.S. District Court for the District of New Jersey in Camden.
Presented by BigVoodoo
New Jersey Law Journal honors lawyers leaving a mark on the legal community in New Jersey with their dedication to the profession.
Consulting Magazine identifies the best firms to work for in the consulting profession.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
The New Jersey Law Revision Commission, an independent legislative commission (N.J.S. 1:12A-1 et seq.), seeks a NJ-licensed atty in good sta...
The Federal Election Commission (FEC) is looking for a passionate and dedicated individual with extensive litigation experience as well as o...
We are seeking an attorney with a minimum of four years of experience in transactional work to join our well-established, nationally renowne...
Amgen sign at its headquarters in Thousand Oaks, California. (Credit: JHVEPhoto/Adobe Stock)
